[go: up one dir, main page]

BR9915623A - Use of 17-ketoesteroid compounds and derivatives, metabolites and precursors thereof in the treatment of malaria and in the treatment of African and American trypanosomiasis - Google Patents

Use of 17-ketoesteroid compounds and derivatives, metabolites and precursors thereof in the treatment of malaria and in the treatment of African and American trypanosomiasis

Info

Publication number
BR9915623A
BR9915623A BR9915623-7A BR9915623A BR9915623A BR 9915623 A BR9915623 A BR 9915623A BR 9915623 A BR9915623 A BR 9915623A BR 9915623 A BR9915623 A BR 9915623A
Authority
BR
Brazil
Prior art keywords
compounds
treatment
metabolites
precursors
derivatives
Prior art date
Application number
BR9915623-7A
Other languages
Portuguese (pt)
Inventor
Clarence Nathaniel Ahlem
James Martin Frincke
Patrick T Prendergast
Original Assignee
Hollis Eden Pharmaceuticals
Colthurst Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hollis Eden Pharmaceuticals, Colthurst Ltd filed Critical Hollis Eden Pharmaceuticals
Publication of BR9915623A publication Critical patent/BR9915623A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Patente de Invenção: <D>"USO DE COMPOSTOS DE 17-CETOESTERóIDES E DERIVADOS, METABOLITOS E PRECURSORES DOS MESMOS NO TRATAMENTO DE MALáRIA E NO TRATAMENTO DE TRIPANOSSOMìASE AFRICANA E AMERICANA"<D>. A invenção refere-se ao uso de compostos de 17-cetoesteróides, assim como derivados, metabolitos e precursores de tais compostos, e sais farmaceuticamente aceitáveis de qualquer um destes compostos, coletivamente definidos neste caso como os "compostos da presente invenção", no tratamento da malária, da Tripanossomíase Africana e da Tripanossomíase Americana, ou para melhorar ou reduzir um ou mais sintomas associados com uma infecção por Plasmodium ou Trypanosoma. A presente invenção também refere-se ao uso de tais compostos no tratamento ou na prevenção de um ou mais tipos de parasitas e/ou uma ou mais doenças causadas por tais parasitas, contra um ou mais tipos de Micoplasma e/ou uma ou mais doenças causadas por tais Micoplasmas e/ou contra uma ou mais das seguintes indicações ou infecções: (a) Leucoplasia peluda, (b) candidose oral, (c) ulcerações-aftosa/herpética/bacteriana de boca, (d) cândida fungal, (e) papiloma vírus humano, (f) moluscum contagiosum, (g) carcinoma oral escamoso, (h) lesões orais de sarcoma Kaposi, (i) periodontite, (j) gengivite necrosante, (k) herpes zoster orafacial e (l) rotavírus, assim como todas as outras indicações e infecções. Os compostos da presente invenção podem também ser usados para melhorar ou reduzir um ou mais dos sintomas associados com qualquer infecção ou estado precário de saúde divulgado neste relatório.Invention Patent: <D> "USE OF COMPOUNDS OF 17-KETOESTEROIDS AND DERIVATIVES, METABOLITES AND PRECURSORS OF THE SAME IN THE TREATMENT OF MALARIA AND THE TREATMENT OF AFRICAN AND AMERICAN TRYPANOSOMYSIS" <D>. The invention relates to the use of 17-ketosteroid compounds, as well as derivatives, metabolites and precursors of such compounds, and pharmaceutically acceptable salts of any of these compounds, collectively defined in this case as the "compounds of the present invention", in the treatment malaria, African trypanosomiasis and American trypanosomiasis, or to improve or reduce one or more symptoms associated with a Plasmodium or Trypanosoma infection. The present invention also relates to the use of such compounds in the treatment or prevention of one or more types of parasites and / or one or more diseases caused by such parasites, against one or more types of Mycoplasma and / or one or more diseases caused by such Mycoplasmas and / or against one or more of the following indications or infections: (a) Hairy leukoplakia, (b) oral candidiasis, (c) mouth-ulcerative / herpetic / bacterial mouth, (d) fungal candida, (and ) human papilloma virus, (f) moluscum contagiosum, (g) oral squamous carcinoma, (h) oral lesions of Kaposi sarcoma, (i) periodontitis, (j) necrotizing gingivitis, (k) orafacial herpes zoster and (l) rotavirus, as well as all other indications and infections. The compounds of the present invention can also be used to ameliorate or reduce one or more of the symptoms associated with any infection or poor state of health disclosed in this report.

BR9915623-7A 1998-11-24 1999-11-24 Use of 17-ketoesteroid compounds and derivatives, metabolites and precursors thereof in the treatment of malaria and in the treatment of African and American trypanosomiasis BR9915623A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10992398P 1998-11-24 1998-11-24
US12408799P 1999-03-11 1999-03-11
US12605699P 1999-03-23 1999-03-23
PCT/US1999/028079 WO2000032201A2 (en) 1998-11-24 1999-11-24 Use of 17-ketosteroids for the treatment of malaria and trypanosomiasis

Publications (1)

Publication Number Publication Date
BR9915623A true BR9915623A (en) 2001-08-14

Family

ID=27380739

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9915623-7A BR9915623A (en) 1998-11-24 1999-11-24 Use of 17-ketoesteroid compounds and derivatives, metabolites and precursors thereof in the treatment of malaria and in the treatment of African and American trypanosomiasis

Country Status (13)

Country Link
EP (1) EP1135138A2 (en)
JP (1) JP2002531407A (en)
KR (2) KR20070004149A (en)
CN (1) CN1348373A (en)
AP (1) AP1584A (en)
AU (2) AU776853B2 (en)
BR (1) BR9915623A (en)
CA (1) CA2356539A1 (en)
HK (1) HK1043319A1 (en)
IL (1) IL142941A0 (en)
NZ (1) NZ511720A (en)
OA (1) OA11715A (en)
WO (1) WO2000032201A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
US20070129282A1 (en) 1998-11-24 2007-06-07 Ahlem Clarence N Pharmaceutical treatments and compositions
EP1223928A2 (en) 1999-07-08 2002-07-24 Patrick Thomas Prendergast Use of flavones, coumarins and related compounds to treat infections
CA2669753C (en) 1999-09-30 2012-06-26 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
US20050101581A1 (en) 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
US7910755B2 (en) 2004-09-29 2011-03-22 Harbor Biosciences, Inc. Stem cell expansion and uses
US8217025B2 (en) 2006-11-17 2012-07-10 Harbor Therapeutics, Inc. Drug screening and treatment methods
KR100786126B1 (en) * 2007-08-14 2007-12-18 주식회사 아바코 A scribe head device and scribe method for maintaining the flatness of the cutting object by a non-contact method

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL194728C (en) * 1987-04-16 2003-01-07 Hollis Eden Pharmaceuticals Pharmaceutical preparation suitable for the prophylaxis or therapy of a retroviral infection or a complication or consequence thereof.
CA2251733A1 (en) * 1996-04-17 1997-10-23 Patrick T. Prendergast Dhea combination therapy
WO1998047516A1 (en) * 1997-04-17 1998-10-29 Prendergast Patrick T Combination therapy utilising 17-ketosteroids and interleukin inhibitors, or interleukin-10 potionally with interleukin inhibitors

Also Published As

Publication number Publication date
CN1348373A (en) 2002-05-08
AP2001002182A0 (en) 2001-06-30
KR20010101073A (en) 2001-11-14
OA11715A (en) 2005-03-14
NZ511720A (en) 2002-12-20
WO2000032201A3 (en) 2000-12-21
WO2000032201A2 (en) 2000-06-08
KR20070004149A (en) 2007-01-05
AU2004237812A1 (en) 2005-01-13
JP2002531407A (en) 2002-09-24
AP1584A (en) 2006-03-01
AU776853B2 (en) 2004-09-23
HK1043319A1 (en) 2002-09-13
AU1745300A (en) 2000-06-19
AU2004237812B2 (en) 2007-11-29
EP1135138A2 (en) 2001-09-26
CA2356539A1 (en) 2000-06-08
IL142941A0 (en) 2002-04-21

Similar Documents

Publication Publication Date Title
TW366347B (en) Antiviral pharmaceutical compositions comprising 1,3-oxathiolane nucleoside analogues
CA2124677A1 (en) Immunopotentiatory agents and physiologically acceptable salts thereof
ES2086644T3 (en) ANOVULATORY PREPARATION FOR HORMONAL CONTRACEPTION.
BR9915623A (en) Use of 17-ketoesteroid compounds and derivatives, metabolites and precursors thereof in the treatment of malaria and in the treatment of African and American trypanosomiasis
ES2125233T3 (en) TREATMENT OF HUMAN RETROVIRAL INFECTIONS WITH 2 &#39;, 3&#39;-DIDESOXYINOSINE.
UA29429C2 (en) Pharmaceutical composition for treatment of viral infections, method for preparation of composition, method for treatment or prophylaxis of aids in human
BRPI0112962B8 (en) pharmaceutical compositions comprising hyaluronic acid, glycyrrhetinic acid and polyvinylpyrrolidone, and use of these compounds in the preparation of medicines
ES2084579T3 (en) USE OF BUSPIRONE IN THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALCOHOL ABUSE.
ES2179193T3 (en) SYNERGIC COMBINATIONS OF ZIDOVUDINA, 1592U89 AND 3TC.
ATE282418T1 (en) ORAL ADMINISTRATION OF EFFECTIVE AMOUNTS OF HYALURONIC ACID
YU75403A (en) Amphotericin b aqueous composition
ES2171440T3 (en) SOLID COMPOSITION MUCOADHESIVA, THERAPEUTICS OR HYGIENIC, FOR ADMINISTRATION BY APPLICATION ON THE MUCOSA ORAL OR NASAL.
BR9908301A (en) Indole derivatives and pharmaceutical compositions comprising the same
BR9911274A (en) Artemisinin derivatives, their preparation processes and the pharmaceutical compositions containing them
TR200102008T2 (en) Use of pyridine derivatives for prophylaxis and treatment of cerebral ischemia.
KR920702226A (en) Antiviral Agents for Human Immunodeficiency Virus
US20040091428A1 (en) Method of preventing and treating mucosal and dermal conditions
CA2150234A1 (en) Combination of atovaquone and proguanil for the treatment of protozoan infection
DE69403063D1 (en) AGAINST VIRUS-ACTIVE NAPHTOCHINONE COMPOUNDS, COMPOSITIONS AND THEIR USE
EP0302836B1 (en) Pharmaceutical compositions for topical use containing miocamycin
BR9909471A (en) Vi and crystalline forms of 5,6-dichloro-2- (isopropylamino) -1-beta-1-ribofuranosyl -1h-benzimidazole, composition, compound, use of 5,6-dichloro-2- (isopropylamino) -1-beta -l-ribofuranosyl -1h-benzimidazole, and processes for the treatment or prophylaxis of a viral infection in humans and for the production of 5,6-dichloro-2- (isopropylamino) -1-beta-l-ribofuranosyl -1h -benzimidazole
MX9700044A (en) Anti-hiv triple combination.
EP1411956B8 (en) Use of oversulfated polysaccharides as inhibitors of hiv
AR040242A1 (en) PHARMACEUTICAL COMPOSITIONS
DE60207824D1 (en) CYTIDINE DIPHOSPHOCHOLIN AGAINST DIABETIC NEUROPATHY

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: ATRAVES DA PETICAO NO 044891 ( 15/082002 ), O REQUERENTE SOLICITOU O EXAME DO PRESENTE E EFETUOU ARETRIBUICAO EQUIVALENTE A 26 REIVINDICACOES EXCEDENTES. NO ENTANTO, NA PETICAO NO 012274 ( 12/03/03) FOI APRESENTADO UM NOVO QUADRO REIVINDICATORIO CONSTANDO 183 REIVINDICACOES ( NUMERACAO ACABA EM 181 DE FORMA EQUIVOCADA ) E RETRIBUICAO EQUIVALENTE A 145 REIVINDICACOES ADIOCIONAIS. DESSE MODO, COMO A RETRIBUICAO FEITA EQUIVALENTE A 171 REIVINDICACOES EXCEDENTES, A FIM DE DAR CONTINUIDADE AO EXAME DO PEDIDO O REQUERENTE DEVERA COMPLEMENTAR A RETRIBUICAO EQUIVALENTE 2 REIVINDICACOES EXECEDENTES

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 8O, 10, ( VIII ) E 32 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.